跳至主要内容
临床试验/NCT05687513
NCT05687513尚未招募早期 1 期

Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through Demethylation

Dongzhimen Hospital, Beijing0 个研究点目标入组 76 人开始时间: 2023年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
尚未招募
发起方
入组人数
76
主要终点
Methylation index

研究概览

简要总结

The goal of this clinical trial is to explore the mechanism of Yisui Granule(YSG) in the treatment of myelodysplastic syndrome(MDS) through demethylation.

Under the same condition of basic western medicine treatment, the treatment group used the same traditional Chinese medicine decoction pieces as YSG, and the control group was given placebo. Through a randomized controlled clinical study, we focused on observing the effects of MDS patients on clinical symptoms (including single symptom), fatigue relief, quality of life, peripheral blood picture, blood transfusion interval and blood transfusion volume, and measured the expression of DNMTs, the expression and methylation level of Wnt3a、β-catenin、SFRP and other indicators, as well as cytokines, were used to explore the mechanism of YSG in the treatment of MDS through demethylation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

treatment group

Experimental

干预措施: Yisui granule (Drug)

control group

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Methylation index

时间窗: 8 weeks

次要结局

未报告次要终点

研究者

发起方
Dongzhimen Hospital, Beijing
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wang Jing

associate professor

Dongzhimen Hospital, Beijing

相似试验